Milestone Scientific (MLSS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2006 | 09-2006 | 06-2006 | 03-2006 | 12-2005 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -3,150 | -2,260 | N/A | N/A | -2,750 |
| Depreciation Amortization | 110 | 90 | N/A | N/A | 110 |
| Accounts receivable | N/A | N/A | N/A | N/A | 41 |
| Accounts payable and accrued liabilities | N/A | N/A | N/A | N/A | 34 |
| Other Working Capital | 840 | 510 | N/A | N/A | -1,510 |
| Other Operating Activity | 550 | 240 | 0 | 0 | 815 |
| Operating Cash Flow | $-1,650 | $-1,420 | $N/A | $N/A | $-3,260 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -10 | -10 | N/A | N/A | -20 |
| Purchase Of Investment | N/A | N/A | N/A | N/A | -6 |
| Purchase Sale Intangibles | N/A | N/A | N/A | N/A | -306 |
| Other Investing Activity | -70 | -30 | 0 | 0 | -304 |
| Investing Cash Flow | $-80 | $-40 | $N/A | $N/A | $-330 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | N/A | N/A | N/A | 1 |
| Other Financing Activity | 0 | 0 | 0 | 0 | 3,449 |
| Financing Cash Flow | $0 | $0 | $N/A | $N/A | $3,450 |
| Beginning Cash Position | 2,890 | 2,890 | N/A | N/A | 3,040 |
| End Cash Position | 1,160 | 1,420 | N/A | N/A | 2,890 |
| Net Cash Flow | $-1,730 | $-1,460 | $N/A | $N/A | $-140 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,650 | -1,420 | N/A | N/A | -3,260 |
| Capital Expenditure | N/A | N/A | N/A | N/A | -23 |
| Free Cash Flow | -1,650 | -1,420 | 0 | 0 | -3,283 |